# Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

- Link: https://www.thailand-business-news.com/pr-news/innovative-drug-update-kexing-biopharm-enrolls-first-subject-in-china-based-phase-i-clinical-trial-of-ophthalmic-innovative-drug-gb10
- Published: 2026-06-04T17:58:00+07:00
- Author: PR Newswire

SHENZHEN, China, June 4, 2026 /PRNewswire/ — Recently, the first subject was enrolled
and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative
ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd.("
Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm. Designed to treat
neovascular age-related macular degeneration (nAMD), the progress of GB10 marks 
a significant milestone in the Company’s accelerating innovative drug R&D pipeline.

GB10 is a high-concentration, ophthalmic protein drug formulation independently 
developed by Shenzhen Kexing. It features a bispecific antibody targeting both VEGF
and Ang-2. With a high concentration of 140 mg/mL, GB10 Injection allows for a smaller
injection volume or higher dosage, thereby extending the dosing interval. It is 
expected to achieve a "once per four months" dosing schedule, significantly improving
patient compliance. Preclinical data indicate international competitiveness of GB10
Injection in terms of both biological activity and in vivo efficacy. In a laser-
induced choroidal neovascularization (CNV) monkey model, it demonstrated effective
inhibition of pathological ocular neovascularization in the fundus.

Neovascular age-related macular degeneration (nAMD) remains a leading cause of blindness
globally among individuals aged over 50. Driven by the rapid growth of the internet,
increased screen time, and an aging population, the clinical demand for ophthalmic
treatments is surging. Therapeutic regimens with extended dosing intervals address
critical clinical pain points, such as high injection frequency and poor patient
compliance.

Kexing Biopharm is simultaneously accelerating its independent R&D of dual-target
antibody ophthalmic pipeline and actively introducing externally developed ophthalmic
products for international markets, including Aflibercept biosimilars and Olopatadine
Hydrochloride eye drops. These efforts aim to expand its global footprint and drive
internationalization through continuous innovation.

Looking ahead, the Company will adhere to its philosophy of "Precise Products, Predictable
Effects, Health Protection," providing high-quality and accessible treatment options
to patients worldwide.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10 ](http://www.prnasia.com/story/archive/4976137_AE76137_0?rand=184833)